BELKIN Laser rebrands as BELKIN Vision

Article

The glaucoma treatment company rebrands to align more closely with goals and direction of the company.

BELKIN Laser rebrands as BELKIN Vision

In a strategic move by the company to align their name with their future, BELKIN Laser will now be known as BELKIN Vision. The Israel-based medical device company will continue to supply fast, accessible glaucoma laser treatment as well as reinforcing their focus on additional ophthalmic challenges.

BELKIN Vision made a splash in the glaucoma treatment industry with their fast, no-contact laser. While other glaucoma treatments—such as daily drops or invasive lasers—pose issues of poor patient adherence and significant time requirements, the BELKIN Vision DSLT (Direct SLT) enhances intraocular fluid drainage in about a second via delivery of a single laser beam to the limbus.

"When we started the company in 2013, we always imagined that it would transport us to the stage we're at today. Now, on the cusp of commercialization, we anticipate a multitude of exciting future applications and wanted to ensure that our company name aligned with that vision. We're confident that BELKIN Vision perfectly reflects our future plans and will capture the hearts and minds of our future customers," said Daria Lemann Blumenthal, CEO of BELKIN Vision.

For more information, visit BELKIN Vision’s website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.